At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform.

LAS VEGAS - October 27, 2022 - (Newswire.com)

Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences (GBLX-OTC), a leading plant-inspired, biopharmaceutical research and drug development company, is demonstrating their AI-enabled drug discovery engines' ability to identify novel plant-inspired pharmaceuticals today at the 10th Annual Drug Discovery Strategic Summit in San Francisco, California. In her session entitled "The Use of an AI-enabled Drug Discovery Engine to Identify Plant-Inspired Pharmaceuticals," Dr. Small-Howard will introduce PhAROS™, Gb Sciences' proprietary AI-enabled drug discovery platform. Dr. Small-Howard will also present case studies establishing how the company has utilized PhAROS™ to combine information from plant-based medical systems with modern in silico drug discovery tools that identify novel plant-inspired therapies for treating critical medical needs. 

"Gb Sciences is combining knowledge from plant-based traditional medical systems with modern in silico drug discovery tools. We are leveraging our AI-enabled platform with its unique database of known traditional medical plant species to uncover novel minimum essential mixtures of ingredients with therapeutic benefits and reduced side effect profiles. Our AI-enabled drug discovery platform also reduces the time and money needed to get results," said Dr. Andrea Small-Howard. "With current drug discovery efforts failing to deliver on some critical medical needs, such as non-opioid treatments for chronic pain or novel options for patients suffering with anxiety and depression, we are establishing the value in exploring plants associated with traditional medicines to discover new drug molecules and simplified mixtures."

Dr. Andrea Small-Howard of Gb Sciences was recently featured on MarketScale's "IDC with Kevin Stevenson" podcast in an episode entitled "Bringing Medicines to Market Faster Through Analytics and Machine Learning" where she discussed the need for digital transformation in the biopharma industry and the fact that Gb Sciences is ahead of the majority of the industry through the development and use of their PhAROS™ platform for drug discovery. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Contact Information:
Madeleine Moench
[email protected]


Press Release Service by Newswire.com

Original Source: TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

Senzo, a global life sciences company developing high-accuracy, low-cost, point-of-care diagnostic technologies, today announced a partnership with BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), in the US Department of Health and Human Services (HHS) to assist in bringing Senzo's Amplified Lateral Flow (ALF) COVID-19 test in achieving U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) to market.

PHILADELPHIA - October 27, 2022 - (Newswire.com)

 This contract follows Senzo's recent announcements about the receipt of ISO 13485:2016 certification, and completing a $2 million Pre-Series A financing led by BioAdvance, to apply the ALF technology to other targets such as Flu A/B, Tuberculosis, HIV, C. diff, Sexual Health, and Hepatitis C.

Senzo's core innovation is its Amplified Lateral Flow (ALF) technology which significantly increases the sensitivity of traditional-format lateral flow tests while maintaining specificity. The end result is a fast, low-cost, easy-to-use lateral flow test with the same accuracy as a PCR test, the industry's gold standard test. The ability to incorporate amplification into a lateral flow test has long been a goal for diagnostics test makers but one which has proven difficult to achieve due to the tendency for amplified tests to return false positives. Senzo recently announced results from a blinded, third-party R&D study demonstrating that its Amplified Lateral Flow (ALF) COVID-19 antigen test was 100% accurate in concordance with PCR testing, even in cases with very low viral levels, which could allow for substantially better and earlier detection of virus compared to current lateral flow tests.

"The faster we can accurately diagnose, the sooner we can take action, begin treatment, and the better the patient outcome. Creating a low-cost, user-friendly diagnostic test which delivers PCR accuracy at the point of care, without the need to send a sample to a laboratory, will improve healthcare— it's that simple. BARDA's support of our ALF technology will be instrumental in helping us advance our ultimate goal of bringing ALF tests to market," said Jeremy Stackawitz, CEO of Senzo.

This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50122C00041.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies focussed on enhanced sensitivity, to create mobile, point-of-care, self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products to bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms. With insights generated at the point of care, patients can make better decisions faster, and healthcare professionals can identify life-threatening diseases at an earlier stage, improving treatment outcomes and saving lives. www.senzo.com.

Contact Information:
Alex Mohacs
Sales & Marketing
[email protected]


Press Release Service by Newswire.com

Original Source: Senzo Receives Funding From the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test

WILMINGTON, N.C. - October 26, 2022 - (Newswire.com)

SportGait, the brain wellness and medical technology company, proudly announced today a partnership with The Carrick Institute, world leader in clinical neuroscience education. The Carrick Institute will incorporate SportGait's platform into their premier Management of Concussion program.

"We have embedded SportGait directly into the coursework while developing one of the world's most comprehensive assessment programs," says Dr. Antonucci, Chiropractic Neurologist and Assistant Professor of Neurology. "When you start looking at concussion, you really can't avoid the fact that it changes individuals' gaits. Even after all symptoms are gone and patients are thinking clearer, the effects of the concussion are still pervasive and persistent, and we can only measure those things realistically by measuring gait."

SportGait, which offers a scalable platform for medical providers, coaches and parents, seeks to bridge the gap between brain wellness and medical technology using a best-in-class, research-backed application developed by a team of doctors and scientists focused in the field of concussion.  

"The Carrick Institute is thrilled to welcome SportGait as a partner," commented Dr. Frederick Carrick, Chancellor and Founder of The Carrick Institute. Bringing their technology into our program will help to ensure we continue to offer the most comprehensive, effective and valuable training on the management of concussions around the world."

Participants of the Management of Concussion course will begin using the SportGait tools later this fall.

"We are enthusiastic by this partnership so that, collectively, our tools in the hands of Carrick-trained clinicians, should only mean better outcomes for patients," says SportGait CEO Chris Newton. 

About SportGait

SportGait is a concussion support and recovery system that offers a scalable platform for medical providers, coaches, and parents. Their array of assessments are best-in-class and research-backed with the goal of bridging brain wellness with medical technology. The scientifically developed system aids and educates users in effectively evaluating and monitoring concussions. SportGait is a highly trusted source of medical technology and was chosen to be the enterprise-wide standard for concussion testing for one of the top five largest hospital systems in the U.S. For more information, please visit https://sportgait.com.

About The Carrick Institute

Founded in 1979, The Carrick Institute is a worldwide leader in applied neuroscience education. The Institute offers more than 100 courses, totaling over 2,000 hours of continuing and post-graduate education in 13 countries and 36 cities. They provide their scholars with the most contemporary science and cutting-edge tools, so that they may serve their patients at the highest levels. For more information, please visit https://www.carrickinstitute.com.

###

Contact Information:
Bethany Vietmeier
Marketing and Public Relations
[email protected]
4127205195


Press Release Service by Newswire.com

Original Source: SportGait Partners With the Carrick Institute, Incorporating Cutting-Edge Concussion Support and Recovery Technology

NEW YORK - October 26, 2022 - (Newswire.com)

Akelos Inc. has been awarded a Phase I/II Fast-Track Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The grant, deriving from a highly competitive application and review process at the NINDS, will provide nearly $700,000 for Phase 1 (years 1-2). If the work reaches NIH benchmarks, Akelos may receive up to an additional $2.990 million for Phase II (years 3-5), with a total of up to $3.69 million to help the company accomplish its goal of developing a potent, non-opioid therapeutic for the treatment of peripheral sensory neuropathic pain.  

Weill Cornell Medicine has received an STTR grant subaward, for which Dr. Peter Goldstein, a professor of anesthesiology and of anesthesiology in neuroscience at the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, is the principal investigator. Dr. Goldstein will work closely with co-investigator Dianna E. Willis, Ph.D., associate director of the Burke Neurological Institute, where she is also lab director of the Laboratory for Axonal and RNA Biology. 

Akelos holds an exclusive, world-wide license to the IP from Weill Cornell Medicine surrounding this research. The research team has been conducting in vitro, in vivo, and in silico screens aimed at the identification of novel lead molecules to treat chronic pain without the risk of addiction. The goals of this project are to optimize the active pharmacophore component of the company's identified lead compound and use that novel molecule to create a new next-generation first-in-class drug for the treatment of peripheral neuropathic pain.  

"We are grateful for the support provided by the NIH for our research and development effort," said Dr. Steven Fox, chairman of Akelos, Inc. "In addition to the financial support, this grant has been reviewed by world-class neurobiologists on the NINDS Review Committee, a robust validation of our unique approach to solving the unmet challenge of treating peripheral neuropathic pain. We look forward to the opportunity represented by this STTR funding to accelerate our path to testing a new, effective treatment for suffering patients." 

As a member of Weill Cornell Medicine's Department of Anesthesiology, Dr. Goldstein received research funding from his department to develop the candidate therapy. Subsequently, he applied for and received funding to further advance and de-risk the technology from the institution's dedicated internal seed technology development program known as the Daedalus Fund for Innovation, part of Weill Cornell Medicine Enterprise Innovation, which aims to accelerate the development of new discoveries by providing funding on a competitive basis for critical path de-risking and proof-of-concept studies that are necessary to leverage commercial investment and partnering arrangements. In 2018, the institution, through Weill Cornell Medicine Enterprise Innovation, licensed the discovery to Akelos Inc. with the express purpose of maturing and commercializing the candidate therapy for clinical application.

Weill Cornell Medicine Enterprise Innovation accelerates the best of biomedical innovation to market, translating groundbreaking research into potentially transformational next-generation care. Enterprise Innovation provides a bridge between academic researchers and industry stakeholders, brokering engagements and alliances, engaging with and educating faculty and trainees about biotech commercialization and business development—which includes patenting, licensing, and marketing—and offering a full suite of entrepreneurship programming, education, mentoring, de-risking and gap funding opportunities and other resources. Weill Cornell Medicine Enterprise Innovation is comprised of the Center for Technology Licensing at Weill Cornell Medicine, the Office of BioPharma Research Alliances, the BioVenture eLabs and the Daedalus Fund for Innovation. 

Dr. Goldstein is a scientific advisory board member of Akelos, Inc. For more information, please contact: 

Akelos Inc. 
Dr. Steven Fox, CEO 
212-953-1544 
[email protected] 

Akelos Inc. Forward-Looking Statement: This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcomes of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. These statements include, among others, those related to: the results of research and development activities, uncertainties relating to preclinical and clinical testing, the cost, timing and outcome of the regulatory development and approval process, our budgets, expenditures and financing plans, our need for substantial additional funds, patent and intellectual property matters, our dependence on third parties, including contract research and contract clinical trial organizations; and market opportunity and competition.

The information contained in this press release is believed to be current as of the date of original issue. Akelos, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact Information:
Dr.Steven Fox
CEO
[email protected]
212-953-1544 


Press Release Service by Newswire.com

Original Source: Akelos Inc. Receives STTR Grant From NINDS

LA VERNE, Calif. - October 26, 2022 - (Newswire.com)

AARDVARK and Sky-Hero are pleased to announce the release of the world's first National Defense Authorization Act (NDAA)-compliant interior use tactical sUAS, LOKI Mk2US. The Mk2US is built to comply with the rigorous standards set forth in the NDAA and the recent Department of Defense black-listing of certain Chinese-made drone parts and technologies.  

In response, Sky-Hero, the world's leading manufacturer of interior tactical robotics, redesigned and resourced the LOKI Mk2 to eliminate all of the covered Chinese components and replace them with European or American items.  

Speaking about this new drone, Yves Coppye, CEO of Sky-Hero, stated: 

"We have been asked by many of our top users around the world to ensure that all major components are built by NATO countries. After two years of work, we are pleased to announce that we have reengineered and redesigned these components and located American or European sources for them."

Jon Becker, AARDVARK's CEO, echoed this by stating: 

"We are extremely excited to see Sky-Hero release an NDAA-compliant version of LOKI. While there are a number of products on the market that claim to be American, in reality, the large majority of drones are simply built with Chinese-made parts and at best assembled in the U.S. LOKI Mk2US has always been made by NATO allies and now every NDAA-covered component will be too." 

The LOKI Mk2US will begin shipping in Q1 of 2023. LOKI Mk2 is sold exclusively in North America by AARDVARK. Visit LOKI.AARDVARKTactical.com to learn more.

About AARDVARK: Founded in 1987, AARDVARK is a leading manufacturer, distributor, and system integrator of products to protect tactical operators from Local, State, Federal, and Military Units. AARDVARK is headquartered in La Verne, CA.

About SKY-HERO: Founded in 2013, Sky-Hero is a dynamic, flexible, fast-growing company specializing in drones and robotics and located in Brussels. With a target market in civil security, their clients range from Police Special Forces to International Security companies, mountain rescue teams, and firefighters.

About LOKI-Mk2 - LOKI Mk2 is a rugged, purpose-built sUAS intended to act as a scout for close-quarter, confined space, and indoor missions. LOKI Mk2 requires no internet service, no GPS, no phone or tablet connection, and has no forced software updates, making it mission capable in seconds from virtually anywhere. LOKI Mk2 performs in almost any lighting condition, seamlessly transitioning from sunlight to complete darkness. 

Contact Information:
Brent Doan
Director of Sales
[email protected]
909-451-6105
Related Files
_F8A2177.jpg
loki2_3qtr_top.sitting.rf_img_1235.jpg



Press Release Service by Newswire.com

Original Source: SKY-HERO and AARDVARK Announce World's First NDAA-Compliant Interior sUAS Platform

Data-Driven Insights Go Beyond Utilization to Assess Market Propensity for Ambulatory Surgery Center Use

PITTSBURGH - October 26, 2022 - (Newswire.com)

Pivotal Analytics, a provider of next-generation business intelligence technology for healthcare investment decisions, has released the findings of an assessment of the hottest U.S. markets for ambulatory surgery center (ASC) investment. The study results underscore the complex dynamics of the healthcare market and the corresponding need to apply a data-driven, analytical approach to healthcare investment decision-making, particularly within a global ASC market that's expected to reach $117 billion by 2027.  

The Pivotal study methodology went beyond the most basic indicator of a market's ASC opportunity — low utilization rates — and added a dimension that's vital to gauging the true opportunity potential: the propensity of a market's healthcare consumers to use an ASC for outpatient procedures. To assess a market's propensity for these alternative sites of care, Pivotal incorporated its proprietary healthcare behavioral profiles to develop a target profile representing the percentage of consumers with the desire and willingness to use an ASC.  

"Identifying opportunities to invest in ASCs or other healthcare facilities often takes a scattershot approach, leading to sub-optimal decisions that don't generate the best returns for healthcare organizations, developers or investors," said Eli Dresner, managing director, client solutions, Pivotal Analytics. "An analytical approach using advanced, proprietary data like healthcare behavioral profiles and ASC propensity yields startlingly different results than simply focusing on markets where ASC use is currently lower than the national average." 

The Pivotal assessment identified the 10 markets with the lowest ambulatory penetration and above-average propensity for ASC use, as well as the 10 markets with the highest propensity for ASC use and below-average utilization. These results pointed to several progressive healthcare markets that have been slow to invest in ASC facilities but are ripe for growth, along with several larger metropolitan areas where patients have a strong desire and willingness to out-migrate for a variety of outpatient procedures. 

The assessment methodology leveraged Pivotal's business intelligence platform and predictive analytics capabilities, as well as unique data assets such as claims, demographics, and healthcare behaviors, that uncover patterns in how patients make healthcare decisions. Given the dynamic nature of the healthcare market and the need for equally dynamic healthcare investment planning approaches, Pivotal intends to update its ASC investment assessment with new data and scenarios over time.    

To learn how Pivotal helps stakeholders make data-driven decisions about ASC investments, download this case study on identifying optimal submarkets for ASC expansion.  

About Pivotal Analytics: 

Pivotal Analytics is a data analytics and insights company seeking to redefine how healthcare systems and their partners identify growth opportunities and optimize real estate investment decisions in a value-based care market. Pivotal empowers healthcare stakeholders to develop better systems of care by enabling consumer-centric decisions of who and what to put where. Pivotal's business intelligence platform integrates traditional and nontraditional data, powerful analytics, and deep healthcare knowledge into hyper-localized insights and geo-based visualizations that locate care opportunities across the U.S. Read our Healthcare System and HRE Developer customer stories, follow us on LinkedIn, or contact us online. 

Contact Information:
Sylvia Marten
Chief Marketing Officer
[email protected]
(202) 571-4001


Press Release Service by Newswire.com

Original Source: Pivotal Analytics Releases Study Findings on Hottest Markets for ASC Investment

eSource is the agile response to promote continuity of clinical trials even in uncertain times.

FREMONT, Calif. - October 26, 2022 - (Newswire.com)

CliniOps, Inc., a leading provider of advanced Digital Clinical Trials, today announced that it has been named in the Gartner annual Hype Cycle™ for Life Science Clinical Development, for five consecutive years. 

Since first acknowledged as a Sample Vendor for eSource solutions in 2018, CliniOps has risen to the challenge of providing solutions fit for the changing needs of the clinical sponsors, clinical research organizations, investigators and patients. During the pandemic, CliniOps was among the clinical trial technologies readily available to impart eSource and other solutions to promote continuity of studies. 

"The eSource technology has become critical for faster collection of clinical trial data. Without the need for any paper recording, data is directly gathered into electronic case report forms (eCRFs) or into a clinical database from source. This direct collection at source is a critical indication of agility and speedy containment of high-quality data. As the need to rapidly find solutions to complex diseases mount, the more critical to have reliable and efficient collection of data from source," said Yerramalli Subramaniam, CTO, CliniOps. 

As an identified Sample Vendor for eSource in the Gartner Hype Cycles five years in a row, CliniOps has become more agile and innovative particularly with the advent of hybrid or decentralized clinical trials (DCTs). 

According to Avik Pal, CEO of CliniOps, "We believe this consecutive recognition of CliniOps by Gartner is significant and is a big boost to the confidence of our team as we continue to work diligently to supply innovative approaches, including DCTs, to clinical trials. With eSource, our tools did not just facilitate efficient data collection and analysis but also contributed to the trend of patient empowerment. Patients were engaged in studies from the comfort and safety of their homes during and even after the pandemic. This trend is here to stay as part of the rise of telehealth."

As the use of advanced digital solutions continues to rise, the eSource profile will become mainstream. Given the chance to use eSource, most would rather do away with paper documents. Those familiar with clinical research using paper documents know very well that duplication of data happens including when the data is transcribed from paper to electronic data capture (EDC) systems. From there, data integrity verification activities can be painstaking. There will be less or none of that with eSource. DCTs are made of eSource and other virtual technologies for agile, less expensive, more efficient studies. 
 

About CliniOps

CliniOps, Inc. is a leading Technology and Data Science company for the Life Science Industry. CliniOps delivers the promise of Hybrid and Decentralized Clinical trials (DCT), making drug trials accessible, inclusive, faster, and efficient. CliniOps' Unified platform approach seamlessly enables home-visit, site-visit, tele-visit and lab-visit, leveraging AI, Mobile, Analytics, Cloud, Sensors and Connected Devices. CliniOps is currently supporting trials across 30+ countries, across all phases and several therapeutic areas. For more information, please visit https://cliniops.com/

Gartner, Hype Cycle for Life Science Clinical Development, 2022, Jeff Smith, Rohan Sinha, July 2022

Disclaimer:

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. Gartner and Hype Cycle are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Contact Information:
CliniOps Media
[email protected]
+1 408.829.4677


Press Release Service by Newswire.com

Original Source: CliniOps Recognized in Gartner® Hype Cycles for Fifth Straight Year